Total Voting Rights
Thalia Therapeutics plc has announced that its total issued share capital now consists of 1,775,720,897 ordinary shares of 0.4 pence each, all carrying voting rights. This figure serves as the denominator for shareholders to calculate their notification obligations regarding interests in the company's share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 1,775,720,897 ordinary shares of 0.4 pence each with voting rights.
The above figure may be used by shareholders as the denominator in calculations to determine whether they are required to notify their interest in, or a change in their interest in, the share capital of the Company.
| Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub https://investors.thaliatx.com/link/PGRqxr |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/ Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang | Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.